Trump announces 100% chip tariff as Apple ups U.S. investment
Elevai Labs, Inc. (ELAB) stock has plummeted to a 52-week low, touching a price level of $1.74. According to InvestingPro data, the company maintains impressive gross profit margins of 71% and holds more cash than debt on its balance sheet, though it's currently burning through cash at a concerning rate. This latest dip underscores a tumultuous period for the company, which has seen its stock value erode by an alarming 97.92% over the past year. Investors have watched with concern as the stock has steadily declined from its previous positions, marking a significant downturn in the company's market valuation and investor confidence. InvestingPro analysis reveals 12 additional key insights about ELAB's financial health and market position. The 52-week low serves as a stark indicator of the challenges Elevai Labs has faced in the market, reflecting broader trends and possibly internal hurdles that have yet to be overcome.
In other recent news, PMGC Holdings has reported a series of important developments. The company has achieved full compliance with Nasdaq's minimum bid price requirement and completed a strategic deal to exercise warrants, raising $1.9 million. Additionally, two of its wholly-owned subsidiaries, Elevai Research Inc. and Elevai Biosciences, Inc., have been rebranded as PMGC Research Inc. and Northstrive Biosciences Inc., respectively.
In terms of leadership, Graydon Bensler has assumed the CEO role at PMGC Research Inc., while Braeden Lichti has stepped in as Chairman. Meanwhile, Carmell Corporation has acquired assets from PMGC Holdings' subsidiary, Elevai Skincare Inc., for approximately $1.1 million, which includes Elevai's skincare and haircare business with a trailing twelve-month revenue of about $2.5 million.
Furthermore, PMGC Holdings' subsidiary, Elevai Biosciences, is preparing for a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration for its novel obesity treatment, EL-22. The company has also signed a Master Services Agreement with KCRN Research, Inc. to support the development of EL-22. These are just some of the recent developments at PMGC Holdings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.